Search
CELL BANK Website

Back Back
Cell No. : Cell Name
RCB1292 : RBE  update : 2022/03/31
CommentHuman intrahepatic cholangiocarcinoma.Please read carefully this information before use.
Comment from the depositor
Terms and conditionsThere is no restriction regarding use for basic researches. In relation to commercial use and use for patent filing, first of all please contact the RIKEN BRC.
Remarks
Order Form Order Form(C-0005.pdf)   MTA(C-0007.pdf)   MTA(C-0007p.pdf)  
Regarding MTA between user institutions and RIKEN BRC, there are two kinds of MTA, not-for-profit academic purpose (C-XXXX) and for-profit research purpose (C-XXXXp) , depending on the sort of user institutions and the purposes of use. Please use an appropriate MTA(to see). In relation to commercial use and use for patent filing, first of all Please contact RIKEN BRC (cellbank.brc@riken.jp).
Basic information Depositor Enjoji, Munechika
Originator Enjoji, Munechika
Year of deposit 1996
Animal human < Mammals
Genus Homo
Species sapiens
Race Japanese
Gender Female
Tissue liver
Disease name cholangiocarcinoma
Classification cancer
Lifespan infinite
Morphology epithelial-like
Cellosaurus(Expasy) CVCL_4896
deposit info
lot info
Medium Medium List
Medium and additives RPMI1640 + 10% FBS
Antibiotics Free
Passage method 0.25% Trypsin
Culture information Passage ratio 1 : 8 split
SC frequency Subculture : once/week, Medium Renewal : 2 times/week
Temperature 37 ℃
CO2 concentration 5 %
Freeze medium Medium + 10% DMSO
Virus (HBV) (-)
Virus (HCV) (-)
Isozyme LD, NP
Chromosome mode 77-87(50) : 77(6),78(7),79(7),80(7),81(5),82(5)/
Images
deposit info
lot info
Reference information Reference 0
User's Publication 54


To topTop
Reference

To topTop
User's Publication
20420  Chui NN, Cheu JW, Yuen VW, Chiu DK, Goh CC, Lee D, Zhang MS, Ng IO, Wong CC.  Inhibition of CMTM4 Sensitizes Cholangiocarcinoma and Hepatocellular Carcinoma to T Cell-Mediated Antitumor Immunity Through PD-L1.  Hepatol Commun  2022    PubMed ID: 34558800   DOI: 10.1002/hep4.1682
20697  Supradit K, Boonsri B, Duangdara J, Thitiphatphuvanon T, Suriyonplengsaeng C, Kangsamaksin T, Janvilisri T, Tohtong R, Yacqub-Usman K, Grabowska AM, Bates DO, Wongprasert K.  Inhibition of serine/arginine-rich protein kinase-1 (SRPK1) prevents cholangiocarcinoma cells induced angiogenesis.  Toxicol In Vitro  2022  105385  PubMed ID: 35568131   DOI: 10.1016/j.tiv.2022.105385
20723  Satow R, Aiga Y, Watanabe T, Ishizuka N, Yoneda A, Fukami K.  Zic family member 5 promotes survival in human pancreatic cancer and cholangiocarcinoma cells.  Biochem Biophys Rep  2022  31:101289  PubMed ID: 35669984   DOI: 10.1016/j.bbrep.2022.101289
20763  Tanaka R, Kimura K, Eguchi S, Ohira G, Tanaka S, Amano R, Tanaka H, Yashiro M, Ohira M, Kubo S.  Interleukin-8 produced from cancer-associated fibroblasts suppresses proliferation of the OCUCh-LM1 cancer cell line.  BMC Cancer  2022  22(1):748  PubMed ID: 35804329   DOI: 10.1186/s12885-022-09847-z
20772  Tanaka M, Kunita A, Yamagishi M, Katoh H, Ishikawa S, Yamamoto H, Abe J, Arita J, Hasegawa K, Shibata T, Ushiku T.  KRAS mutation in intrahepatic cholangiocarcinoma: linkage with metastasis-free survival and reduced E-cadherin expression.  Liver Int  2022    PubMed ID: 35833881   DOI: 10.1111/liv.15366
20794  Chen S, Nishi M, Morine Y, Yoshikawa K, Tokunaga T, Kashihara H, Takasu C, Wada Y, Yoshimoto T, Nakamoto A, Sakai T, Shimada M.  Polymethoxylated flavone sudachitin is a safe anticancer adjuvant that targets glycolysis in cancer-associated fibroblasts.  Oncol Lett  2022  24(1):236  PubMed ID: 35720469   DOI: 10.3892/ol.2022.13356
20925  Wu CE, Chen CP, Pan YR, Jung SM, Chang JW, Chen JS, Yeh CN, Lunec J.  In vitro and in vivo study of GSK2830371 and RG7388 combination in liver adenocarcinoma.  Am J Cancer Res  2022  12(9):4399-4410  PubMed ID: 36225643  
13539  Nagaoka K, Ogawa K, Ji C, Cao KY, Bai X, Mulla J, Cheng Z, Wands JR, Huang CK.  Targeting Aspartate Beta-Hydroxylase with the Small Molecule Inhibitor MO-I-1182 Suppresses Cholangiocarcinoma Metastasis  Dig Dis Sci  2021  66(4):1080-1089  PubMed ID: 32445050   DOI: 10.1007/s10620-020-06330-2
15516  Hozaka Y, Seki N, Tanaka T, Asai S, Moriya S, Idichi T, Wada M, Tanoue K, Kawasaki Y, Mataki Y, Kurahara H, Ohtsuka T.  Molecular Pathogenesis and Regulation of the miR-29-3p-Family: Involvement of ITGA6 and ITGB1 in Intra-Hepatic Cholangiocarcinoma  ancers (Basel)   2021  13(11):2804  PubMed ID: 34199886   DOI: 10.3390/cancers13112804
16118  Ota Y, Takahashi K, Otake S, Tamaki Y, Okada M, Yan I, Aso K, Fujii S, Patel T, Haneda M  Extracellular RNA transfer from non-malignant human cholangiocytes can promote cholangiocarcinoma growth  FEBS Open Bio  2021  11(12):3276-329  PubMed ID: 34510808   DOI: 10.1002/2211-5463.13294
12038  Yamanaka T, Harimoto N, Yokobori T, Muranushi R, Hoshino K, Hagiwara K, Gantumur D, Handa T, Ishii N, Tsukagoshi M, Igarashi T, Tanaka H, Watanabe A, Kubo N, Araki K, Shirabe K.  Nintedanib inhibits intrahepatic cholangiocarcinoma aggressiveness via suppression of cytokines extracted from activated cancer-associated fibroblasts.  Br. J. Cancer  2020    PubMed ID: 32015511   DOI: 10.1038/s41416-020-0744-7
12462  Yoshino J, Akiyama Y, Shimada S, Ogura T, Ogawa K, Ono H, Mitsunori Y, Ban D, Kudo A, Yamaoka S, Tanabe M, Tanaka S.  Loss of ARID1A induces a stemness gene ALDH1A1 expression with histone acetylation in the malignant subtype of cholangiocarcinoma  Carcinogenesis  2020  41(6):734-742  PubMed ID: 31665232   DOI: 10.1093/carcin/bgz179
13005  Hsieh CH, Chu CY, Lin SE, Yang YSH, Chang HS, Yen Y.  TESC Promotes TGF-α/EGFR-FOXM1-Mediated Tumor Progression in Cholangiocarcinoma.  Cancers (Basel)  2020    PubMed ID: 32365487   DOI: 10.3390/cancers12051105
13336  Pan YR, Wu CE, Yeh CN.  ATM Inhibitor Suppresses Gemcitabine-Resistant BTC Growth in a Polymerase θ Deficiency-Dependent Manner.  Biomolecules  2020    PubMed ID: 33182492   DOI: 10.3390/biom10111529
13579  Arora M, Bogenberger JM, Abdelrahman A, Leiting JL, Chen X, Egan JB, Kasimsetty A, Lenkiewicz E, Malasi S, Uson PLS, Nagalo BM, Zhou Y, Salomao MA, Kosiorek HE, Braggio E, Barrett MT, Truty MJ, Borad MJ.  Evaluation of NUC-1031: a first-in-class ProTide in biliary tract cancer  Cancer Chemother Pharmacol  2020  85(6):1063-1078  PubMed ID: 32440762   DOI: 10.1007/s00280-020-04079-z
13917  Tamai K, Nakamura-Shima M, Shibuya-Takahashi R, Kanno SI, Yasui A, Mochizuki M, Iwai W, Wakui Y, Abue M, Yamamoto K, Miura K, Mizuma M, Unno M, Kawamura S, Sato I, Yasuda J, Yamaguchi K,   BEX2 suppresses mitochondrial activity and is required for dormant cancer stem cell maintenance in intrahepatic cholangiocarcinoma  Sci Rep  2020  10(1):21592  PubMed ID: 33299012   DOI: 10.1038/s41598-020-78539-0
16133  Fu W, Yu G, Liang J, Fan P, Dong K, Zhang B, Chen X, Zhu H, Chu L.  miR-144-5p and miR-451a Inhibit the Growth of Cholangiocarcinoma Cells Through Decreasing the Expression of ST8SIA4  Front Oncol  2020  10:563486  PubMed ID: 33520692   DOI: 10.3389/fonc.2020.563486
11443  Brun S, Bassissi F, Serdjebi C, Novello M, Tracz J, Autelitano F, Guillemot M, Fabre P, Courcambeck J, Ansaldi C, Raymond E, Halfon P.  GNS561, a new lysosomotropic small molecule, for the treatment of intrahepatic cholangiocarcinoma.  Invest New Drugs  2019    PubMed ID: 30778887   DOI: 10.1007/s10637-019-00741-3
14816  Goyal L, Shi L, Liu LY, Fece de la Cruz F, Lennerz JK, Raghavan S, Leschiner I, Elagina L, Siravegna G, Ng RWS, Vu P, Patra KC, Saha SK, Uppot RN, Arellano R, Reyes S, Sagara T, Otsuki S, Nadres B, Shahzade HA, Dey-Guha I, Fetter IJ, Baiev I, Van Seventer EE, Murphy JE, Ferrone CR, Tanabe KK, Deshpande V, Harding JJ, Yaeger R, Kelley RK, Bardelli A, Iafrate AJ, Hahn WC, Benes CH, Ting DT, Hirai H, Getz G, Juric D, Zhu AX, Corcoran RB, Bardeesy N.  TAS-120 Overcomes Resistance to ATP-Competitive FGFR Inhibitors in Patients with FGFR2 Fusion-Positive Intrahepatic Cholangiocarcinoma  Cancer Discov  2019  9(8):1064-1079  PubMed ID: 31109923   DOI: 10.1158/2159-8290.CD-19-0182
10658  Yokoi K, Kobayashi A, Motoyama H, Kitazawa M, Shimizu A, Notake T, Yokoyama T, Matsumura T, Takeoka M, Miyagawa SI.  Survival pathway of cholangiocarcinoma via AKT/mTOR signaling to escape RAF/MEK/ERK pathway inhibition by sorafenib.  Oncol. Rep.  2018  39:843-850  PubMed ID: 29251327   DOI: 10.3892/or.2017.6153
10816  Ota Y, Takahashi K, Otake S, Tamaki Y, Okada M, Aso K, Makino Y, Fujii S, Ota T, Haneda M.  Extracellular vesicle-encapsulated miR-30e suppresses cholangiocarcinoma cell invasion and migration via inhibiting epithelial-mesenchymal transition.  Oncotarget  2018  9:16400-16417  PubMed ID: 29662654   DOI: 10.18632/oncotarget.24711
11206  Yamaoka R, Ishii T, Kawai T, Yasuchika K, Miyauchi Y, Kojima H, Katayama H, Ogiso S, Fukumitsu K, Uemoto S.  CD90 expression in human intrahepatic cholangiocarcinoma is associated with lymph node metastasis and poor prognosis.  J Surg Oncol  2018    PubMed ID: 30196535   DOI: 10.1002/jso.25192
4337  Nakagawa S, Okabe H, Ouchi M, Tokunaga R, Umezaki N, Higashi T, Kaida T, Arima K, Kitano Y, Kuroki H, Mima K, Nitta H, Imai K, Hashimoto D, Yamashita YI, Chikamoto A, Baba H.  Enhancer of zeste homolog 2 (EZH2) regulates tumor angiogenesis and predicts recurrence and prognosis of intrahepatic cholangiocarcinoma.  HPB (Oxford)  2018    PubMed ID: 29759640   DOI: 10.1016/j.hpb.2018.03.018
4338  Fujiwara H, Tateishi K, Kato H, Nakatsuka T, Yamamoto K, Tanaka Y, Ijichi H, Takahara N, Mizuno S, Kogure H, Matsubara S, Nakai Y, Koike K.  Isocitrate dehydrogenase 1 mutation sensitizes intrahepatic cholangiocarcinoma to the BET inhibitor JQ1.  Cancer Sci.  2018    PubMed ID: 30156013   DOI: 10.1111/cas.13784
4339  Mori A, Masuda K, Ohtsuka H, Shijo M, Ariake K, Fukase K, Sakata N, Mizuma M, Morikawa T, Hayashi H, Nakagawa K, Motoi F, Naitoh T, Fujishima F, Unno M.  FBXW7 modulates malignant potential and cisplatin-induced apoptosis in cholangiocarcinoma through NOTCH1 and MCL1.  Cancer Sci.  2018    PubMed ID: 30302867   DOI: 10.1111/cas.13829
4486  Nepal C, O'Rourke CJ, Oliveira DVNP, Taranta A, Shema S, Gautam P, Calderaro J, Barbour A, Raggi C, Wennerberg K, Wang XW, Lautem A, Roberts LR, Andersen JB.  Genomic perturbations reveal distinct regulatory networks in intrahepatic cholangiocarcinoma.  Hepatology  2018  68(3):949-963  PubMed ID: 29278425   DOI: 10.1002/hep.29764
5802  Eguchi T et al  Organoids with cancer stem cell-like properties secrete exosomes and HSP90 in a 3D nanoenvironment.  PLoS One  2018  13(2):e0191109.  PubMed ID: 29415026   DOI: 10.1371/journal.pone.0191109
14913  Lin G, Lin KJ, Wang F, Chen TC, Yen TC, Yeh TS.  Synergistic antiproliferative effects of an mTOR inhibitor (rad001) plus gemcitabine on cholangiocarcinoma by decreasing choline kinase activity  Dis Model Mech  2018  11(8):dmm03305  PubMed ID: 29666220   DOI: 10.1242/dmm.033050
14942  Wang J, Dong M, Xu Z, Song X, Zhang S, Qiao Y, Che L, Gordan J, Hu K, Liu Y, Calvisi DF, Chen X.  Notch2 controls hepatocyte-derived cholangiocarcinoma formation in mice  Oncogene  2018  ;37(24):3229-3242  PubMed ID: 29545603   DOI: 10.1038/s41388-018-0188-1
10290  Quintavalle C, Burmeister K, Piscuoglio S, Quagliata L, Karamitopoulou E, Sepe R, Fusco A, Terracciano LM, Andersen JB, Pallante P, Matter MS.  High mobility group A1 enhances tumorigenicity of human cholangiocarcinoma and confers resistance to therapy.  Mol. Carcinog.  2017  56:2146-2157  PubMed ID: 28467612   DOI: 10.1002/mc.22671
10333  Huang G-, Liu TT, Weng SW, You HL, Wei YC, Chen CH, Eng HL, Huang WT.  CUL4A overexpression as an independent adverse prognosticator in intrahepatic cholangiocarcinoma.  BMC Cancer  2017  17:395  PubMed ID: 28576144   DOI: 10.1186/s12885-017-3389-z
10501  Kushibiki T, Noji T, Ebihara Y, Hontani K, Ono M, Kuwabara S, Nakamura T, Tsuchikawa T, Okamura K, Ishizuka M, Hirano S.  5-Aminolevulinic-acid-mediated Photodynamic Diagnosis Enhances the Detection of Peritoneal Metastases in Biliary Tract Cancer in Mice.  In Vivo  2017  31:905-908  PubMed ID: 28882957   DOI: 10.21873/invivo.11145
14252  Maki T, Ikeda H, Kuroda A, Kyogoku N, Yamamura Y, Tabata Y, Abiko T, Tsuchikawa T, Hida Y, Shichinohe T, Tanaka E, Kaga K, Hatanaka K, Matsuno Y, Imai N, Hirano S.  Differential detection of cytoplasmic Wilms tumor 1 expression by immunohistochemistry, western blotting and mRNA quantification  Int J Oncol  2017  50(1):129-140.  PubMed ID: 27922671   DOI: 10.3892/ijo.2016.3786
14528  Yagai T, Matsui S, Harada K, Inagaki FF, Saijou E, Miura Y, Nakanuma Y, Miyajima A, Tanaka M.  Expression and localization of sterile alpha motif domain containing 5 is associated with cell type and malignancy of biliary tree  PLoS One  2017  12(4):e0175355  PubMed ID: 28388653   DOI: 10.1371/journal.pone.0175355
9923  Aoki S, Mizuma M, Takahashi Y, Haji Y, Okada R, Abe T, Karasawa H, Tamai K, Okada T, Morikawa T, Hayashi H, Nakagawa K, Motoi F, Naitoh T, Katayose Y, Unno M.  Aberrant activation of Notch signaling in extrahepatic cholangiocarcinoma: clinicopathological features and therapeutic potential for cancer stem cell-like properties.  BMC Cancer  2016  16:854  PubMed ID: 27821106   DOI: 10.1186/s12885-016-2919-4
3735  Saha SK et al  Isocitrate Dehydrogenase Mutations Confer Dasatinib Hypersensitivity and SRC Dependence in Intrahepatic Cholangiocarcinoma.  Cancer Discov  2016  6(7):727-39  PubMed ID: 27231123   DOI: 10.1158/2159-8290.CD-15-1442
12878  Yang SH, Lin HY, Changou CA, Chen CH, Liu YR, Wang J, Jiang X, Luh F, Yen Y.  Integrin β3 and LKB1 are independently involved in the inhibition of proliferation by lovastatin in human intrahepatic cholangiocarcinoma  Oncotarget  2016  7(1):362-73  PubMed ID: 26517522   DOI: 10.18632/oncotarget.6238
5025  Sakamoto K, Imai K, Higashi T, Taki K, Nakagawa S, Okabe H, Nitta H, Hayashi H, Chikamoto A, Ishiko T, Beppu T, Baba H.  Significance of P-cadherin overexpression and possible mechanism of its regulation in intrahepatic cholangiocarcinoma and pancreatic cancer.  Cancer Sci  2015  106(9):1153-62  PubMed ID: 26132727   DOI: 10.1111/cas.12732
15203  Wang J, Zhang K, Wang J, Wu X, Liu X, Li B, Zhu Y, Yu Y, Cheng Q, Hu Z, Guo C, Hu S, Mu B, Tsai CH, Li J, Smith L, Yang L, Liu Q, Chu P, Chang V, Zhang B, Wu M, Jiang X, Yen Y.  Underexpression of LKB1 tumor suppressor is associated with enhanced Wnt signaling and malignant characteristics of human intrahepatic cholangiocarcinoma  Oncotarget  2015  6(22):18905-20  PubMed ID: 26056085   DOI: 10.18632/oncotarget.4305
12541  Soejima Y, Inoue M, Takahashi Y, Uozaki H, Sawabe M, Fukusato T.  ntegrins αvβ6, α6β4 and α3β1 are down-regulated in cholangiolocellular carcinoma but not cholangiocarcinoma  Hepatol Res  2014  44(14):E320-34  PubMed ID: 24552196   DOI: 10.1111/hepr.12312
14393  Nakagawa S, Sakamoto Y, Okabe H, Hayashi H, Hashimoto D, Yokoyama N, Tokunaga R, Sakamoto K, Kuroki H, Mima K, Beppu T, Baba H.  Epigenetic therapy with the histone methyltransferase EZH2 inhibitor 3-deazaneplanocin A inhibits the growth of cholangiocarcinoma cells  Oncol Rep  2014  31(2):983-8  PubMed ID: 24337160   DOI: 10.3892/or.2013.2922
16018  Jachin S, Bae JS, Sung JJ, Park HS, Jang KY, Chung MJ, Kim DG, Moon WS.  The role of nuclear EpICD in extrahepatic cholangiocarcinoma: association with β-catenin  Int J Oncol   2014  45(2):691-8  PubMed ID: 24888903   DOI: 10.3892/ijo.2014.2472
12544  Kumagai A, Fukushima J, Takikawa H, Fukuda T, Fukusato T.  Enhanced expression of farnesoid X receptor in human hepatocellular carcinoma  Hepatol Res  2013  43(9):959-69  PubMed ID: 23369163   DOI: 10.1111/hepr.12047
16575  Jamiyandorj U, Bae JS, Noh SJ, Jachin S, Choi JE, Jang KY, Chung MJ, Kang MJ, Lee DG, Moon WS.  Expression of peptidyl-prolyl isomerase PIN1 and its role in the pathogenesis of extrahepatic cholangiocarcinoma  Oncol Lett  2013  6(5):1421-1426  PubMed ID: 24179535   DOI: 10.3892/ol.2013.1525
17161  Lin Y, Zhang B, Liang H, Lu Y, Ai X, Zhang B, Chen X.  JNK inhibitor SP600125 enhances TGF-β-induced apoptosis of RBE human cholangiocarcinoma cells in a Smad-dependent manner  Mol Med Rep  2013  8(6):1623-9  PubMed ID: 24100678   DOI: 10.3892/mmr.2013.1711
5863  Yoshii Y, Waki A, Yoshida K, Kakezuka A, Kobayashi M, Namiki H, Kuroda Y, Kiyono Y, Yoshii H, Furukawa T, Asai T, Okazawa H, Gelovani JG, Fujibayashi Y.  The use of nanoimprinted scaffolds as 3D culture models to facilitate spontaneous tumor cell migration and well-regulated spheroid formation.  Biomaterials  2011  32(26):6052-8  PubMed ID: 21640378   DOI: 10.1016/j.biomaterials.2011.04.076
8365  Ishii T, Yasuchika K, Suemori H, Nakatsuji N, Ikai I, Uemoto S.  Alpha-fetoprotein producing cells act as cancer progenitor cells in human cholangiocarcinoma.  Cancer Lett.  2010  294:25-34  PubMed ID: 20149523   DOI: 10.1016/j.canlet.2010.01.019
6410  Danjoh I, Sone H, Noda N, Iimura E, Nagayoshi M, Saijo K, Hiroyama T, Nakamura Y.  Is parainfluenza virus a threatening virus for human cancer cell lines?  Hum Cell  2009  22(3):81-4  PubMed ID: 19624309   DOI: 10.1111/j.1749-0774.2009.00071.x
12770  Xu HL, Inagaki Y, Seyama Y, Sugawara Y, Kokudo N, Nakata M, Wang FS, Tang W.  Expression of KL-6 mucin, a human MUC1 mucin, in intrahepatic cholangiocarcinoma and its potential involvement in tumor cell adhesion and invasion  Life Sci  2009  85(9-10):395-400  PubMed ID: 19631667   DOI: 10.1016/j.lfs.2009.07.004
3575  Komori J, Marusawa H, Machimoto T, Endo Y, Kinoshita K, Kou T, Haga H, Ikai I, Uemoto S, Chiba T.  Activation-induced cytidine deaminase links bile duct inflammation to human cholangiocarcinoma.  Hepatology  2008  47(3):888-96  PubMed ID: 18306229   DOI: 10.1002/hep.22125
3077  Nakatsu N, Yoshida Y, Yamazaki K, Nakamura T, Dan S, Fukui Y, Yamori T  Chemosensitivity profile of cancer cell lines and identification of genes determining chemosensitivity by an integrated bioinformatical approach using cDNA arrays.  Mol Cancer Ther  2005  4:399-412  PubMed ID: 15767549   DOI: 10.1158/1535-7163.MCT-04-0234
3334  Obama, Kazutaka, Ura, Katsuaki, Satoh, Seiji, Nakamura, Yusuke, Furukawa, Yoichi  Up-regulation of PSF2, a member of the GINS multiprotein complex, in intrahepatic cholangiocarcinoma  Oncol Res  2005  14:701-706  PubMed ID: 16077978  
3346  Yokoo, Hideki, Kondo, Tadashi, Fujii, Kazuyasu, Yamada, Tesshi, Todo, Satoru, Hirohashi, Setsuo  Proteomic signature corresponding to alpha fetoprotein expression in liver cancer cells.  Hepatology  2004  40:609-17  PubMed ID: 15349899   DOI: 10.1002/hep.20372
3703  Sanada T, Yokoi S, Arii S, Yasui K, Imoto I, Inazawa J.  Skp2 overexpression is a p27Kip1-independent predictor of poor prognosis in patients with biliary tract cancers.  Cancer Sci  2004  95(12):969-76  PubMed ID: 15596046   DOI: 10.1111/j.1349-7006.2004.tb03185.x



Back Back Return Top Page